Opinion · United States Court of Appeals for the Federal Circuit

IN RE OMEPRAZOLE PATENT LITIGATION, 412 Fed.Appx. 297 (Fed. Cir. 2010)

In re OMEPRAZOLE Pat. LITIGATION. Astrazeneca AB, Aktiebolaget Hassle,KBI-E, Inc., KBI, Inc., & Astrazeneca LP, Plaintiffs-Appellees, v.Mylan Laboratories Inc. (now known as Mylan Inc.), Mylan PharmaceuticalsInc., Laboratories Dr. Esteve, S.A. & Esteve Quimica, S.A.,Defendants-Appellants., 412 F. App'x 297 (Fed. Cir. 2010)

Type
Opinion
Court
United States Court of Appeals for the Federal Circuit
Jurisdiction
Federal
Date
2011-03-08
Topic
general

IN RE OMEPRAZOLE PATENT LITIGATION, 412 Fed.Appx. 297 (Fed. Cir. 2010) In re OMEPRAZOLE PATENT LITIGATION. Astrazeneca AB, Aktiebolaget Hassle,KBI-E, Inc., KBI, Inc., and Astrazeneca LP, Plaintiffs-Appellees, v.Mylan Laboratories Inc. (now known as Mylan Inc.), Mylan PharmaceuticalsInc., Laboratories Dr. Esteve, S.A. and Esteve Quimica, S.A.,Defendants-Appellants.

Citator

UpLaw has not yet analyzed IN RE OMEPRAZOLE PATENT LITIGATION, 412 Fed.Appx. 297 (Fed. Cir. 2010). The absence of a flag is not a finding that it is good law.